KR102484678B1 - 미분 톨카폰을 포함하는 서방성 조성물 - Google Patents

미분 톨카폰을 포함하는 서방성 조성물 Download PDF

Info

Publication number
KR102484678B1
KR102484678B1 KR1020197004664A KR20197004664A KR102484678B1 KR 102484678 B1 KR102484678 B1 KR 102484678B1 KR 1020197004664 A KR1020197004664 A KR 1020197004664A KR 20197004664 A KR20197004664 A KR 20197004664A KR 102484678 B1 KR102484678 B1 KR 102484678B1
Authority
KR
South Korea
Prior art keywords
tolcapone
tablet
weight
cellulose
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197004664A
Other languages
English (en)
Korean (ko)
Other versions
KR20190034563A (ko
Inventor
리카트 안나 나디
네르게 조셉 마리아 수네
볼라노 누리아 레이그
보로나트 라울 인사
감빈 오스카르 우에르타스
그라스 산티아고 에스테바
모르 갈.라 페리코트
Original Assignee
솜 이노베이션 바이오테크, 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 솜 이노베이션 바이오테크, 에스.에이. filed Critical 솜 이노베이션 바이오테크, 에스.에이.
Publication of KR20190034563A publication Critical patent/KR20190034563A/ko
Application granted granted Critical
Publication of KR102484678B1 publication Critical patent/KR102484678B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197004664A 2016-07-29 2017-07-28 미분 톨카폰을 포함하는 서방성 조성물 Active KR102484678B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382372.7A EP3275433A1 (en) 2016-07-29 2016-07-29 Sustained release composition comprising micronized tolcapone
EP16382372.7 2016-07-29
PCT/EP2017/069168 WO2018019997A1 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Publications (2)

Publication Number Publication Date
KR20190034563A KR20190034563A (ko) 2019-04-02
KR102484678B1 true KR102484678B1 (ko) 2023-01-03

Family

ID=56571284

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197004664A Active KR102484678B1 (ko) 2016-07-29 2017-07-28 미분 톨카폰을 포함하는 서방성 조성물

Country Status (12)

Country Link
US (2) US11883538B2 (OSRAM)
EP (2) EP3275433A1 (OSRAM)
JP (1) JP7047236B2 (OSRAM)
KR (1) KR102484678B1 (OSRAM)
CN (1) CN109789100A (OSRAM)
AU (1) AU2017303333B2 (OSRAM)
DK (1) DK3490535T3 (OSRAM)
ES (1) ES2891355T3 (OSRAM)
MX (1) MX391116B (OSRAM)
PT (1) PT3490535T (OSRAM)
RU (1) RU2750670C2 (OSRAM)
WO (1) WO2018019997A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112053A1 (en) 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
WO2012066538A1 (en) 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ332861A (en) 1996-05-20 2000-08-25 G Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
DK1071402T3 (da) * 1998-04-09 2007-02-19 Hoffmann La Roche Fremgangsmåde til af partikler med (sub)mikronstörrelse ved oplösning i komprimeret gas og overfladeaktive stoffer
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
CA2510320C (en) * 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
EA013161B1 (ru) * 2005-06-08 2010-02-26 Орион Корпорейшн Дозированная форма для перорального применения
DK2686310T5 (en) 2011-03-14 2018-07-09 Boehringer Ingelheim Int Benzodioxan-INHIBITORERAFLEUKOTRIEN PRODUCTION
PT2770988T (pt) * 2011-10-24 2016-09-05 Som Innovation Biotech S L Nova terapêutica para a amiloidose associada à transtirretina
US20130195973A1 (en) * 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
US20160022573A1 (en) * 2013-03-13 2016-01-28 Neuroderm, Ltd. Method for treatment of parkinson's disease
JP6538063B2 (ja) * 2013-11-05 2019-07-03 シンアジャル コーポレイション 口を介する連続的薬物送達のためのデバイスおよび方法
CN107072973A (zh) * 2014-09-04 2017-08-18 劳波索尔制药有限公司 含左旋多巴、多巴胺脱羧酶抑制剂和comt抑制剂的药物组合物及其施用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112053A1 (en) 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
WO2012066538A1 (en) 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same

Also Published As

Publication number Publication date
MX391116B (es) 2025-03-21
EP3490535A1 (en) 2019-06-05
EP3490535B1 (en) 2021-07-14
DK3490535T3 (da) 2021-10-04
BR112019001826A2 (pt) 2019-05-07
WO2018019997A1 (en) 2018-02-01
RU2019103647A (ru) 2020-08-28
AU2017303333B2 (en) 2023-03-30
RU2019103647A3 (OSRAM) 2020-10-12
MX2019001190A (es) 2019-09-06
JP2019523305A (ja) 2019-08-22
RU2750670C2 (ru) 2021-06-30
US11883538B2 (en) 2024-01-30
US20240216282A1 (en) 2024-07-04
PT3490535T (pt) 2021-09-30
KR20190034563A (ko) 2019-04-02
EP3275433A1 (en) 2018-01-31
AU2017303333A1 (en) 2019-03-14
US12220487B2 (en) 2025-02-11
US20190167596A1 (en) 2019-06-06
CA3032211A1 (en) 2018-02-01
CN109789100A (zh) 2019-05-21
ES2891355T3 (es) 2022-01-27
JP7047236B2 (ja) 2022-04-05

Similar Documents

Publication Publication Date Title
Basak et al. Formulation and release behaviour of sustained release ambroxol hydrochloride HPMC matrix tablet.
DE69905380T2 (de) Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
JP5653218B2 (ja) アンジオテンシン受容体アンタゴニスト／ブロッカーおよび中性エンドペプチダーゼ（ｎｅｐ）阻害剤の超構造に基づく二作用性医薬組成物
AU2014225449B2 (en) Stabilization of moisture-sensitive drugs
PT1789021E (pt) Formulação de comprimidos de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável
BR112014026292B1 (pt) Comprimido oralmente desintegrável, e, processo para a produção de um comprimido oralmente desintegrável
US20250249015A1 (en) Novel rivaroxaban formulation
US12220487B2 (en) Sustained release compositions comprising micronized tolcapone
WO2006103551A1 (en) Controlled release formulations of oxycodone
CA3032211C (en) Sustained release composition comprising micronized tolcapone
JP2017075139A (ja) 低用量薬物を含有する口腔内崩壊錠
JP6002869B1 (ja) ジエノゲスト含有錠剤
BRPI0619934A2 (pt) composição farmacêutica de liberação prolongada, processo para a preparação de uma composição, uso de uma composição, e, uso de uma composição
TWI651085B (zh) Ｎ－［５－［２－（３，５－二甲氧基苯基）乙基］－２ｈ－吡唑－３－基］－４－［（３ｒ，５ｓ）－３，５－二甲基哌－１－基］苯甲醯胺之醫藥調配物
BR112019001826B1 (pt) Composição de liberação prolongada compreendendo tolcapone micronizada
JPH02282322A (ja) 有効物質の浸食制御による放出システムおよびその製造方法
HK40008562A (en) Sustained release composition comprising micronized tolcapone
JP2017075138A (ja) ジエノゲスト含有錠剤
JP6002870B1 (ja) 低用量薬物を含有する口腔内崩壊錠
CN103877041B (zh) 一种吡罗昔康分散片及其制备方法
EP2732812A1 (de) Pramipexol-Retardtablettenformulierung
BG65912B1 (bg) Лекарствена форма на комбиниран препарат и метод за нейното получаване
JP2013227303A (ja) トリクロルメチアジドおよび結晶セルロースを含有する固形製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190215

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200619

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220225

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220922

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220225

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220922

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220511

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20221004

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220928

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220922

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220511

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221230

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221230

End annual number: 3

Start annual number: 1

PG1601 Publication of registration